Roche
NEWS
On Thursday, FTC staff reviewing Roche’s $4.8 billion bid for Spark gave the deal a thumbs up after reviewing the potential merger.
When it comes to specific attributes, having the opportunity to do interesting and meaningful work, securing a competitive salary and having access to quality health benefits were the most important. Here are some differences when it comes to generational priorities.
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
Last week was busy for clinical trial news. Here’s a look.
Roche announced results from its Phase III PEMPHIX trial evaluated MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris.
Roche Vice Chairman Andre Hoffman is warning that short-term thinking is killing the planet and that corporations must engage in long-term sustainable strategies that limit any environmental harm and can help reverse some of the damage that’s already been done.
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Researchers from Genentech and its parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.
JOBS
IN THE PRESS